Renaissance Capital logo

PhaseBio Pharmaceuticals Priced, Nasdaq: PHAS

Phase 2 biotech developing therapies for rare cardiopulmonary diseases.

Industry: Health Care

First Day Return: 0.0%

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. Our lead product candidate, PB2452, is a novel reversal agent for the antiplatelet drug ticagrelor, which we are developing for the treatment of patients experiencing major bleeding or those who require urgent surgery. We recently completed a Phase 1 clinical trial of PB2452 in healthy subjects. Our second product candidate, PB1046, is a once-weekly fusion protein currently in a Phase 2b clinical trial for the treatment of pulmonary arterial hypertension, or PAH. PB1046 utilizes our proprietary half-life extending elastin-like polypeptide, or ELP, technology, which also serves as the engine for our preclinical pipeline.
more less

PhaseBio Pharmaceuticals (PHAS) Performance